Patents Issued in August 6, 2020
  • Antibody Drug Conjugates with Cell Permeable BCL-XL Inhibitors
    Publication number: 20200246323
    Abstract: Small molecule Bcl-xL inhibitors and Antibody Drug Conjugates (ADCs) comprising small molecule Bcl-xL inhibitors are disclosed herein. The Bcl-xL inhibitors and ADCs of the disclosure are useful for, among other things, inhibiting anti-apoptotic Bcl-xL proteins as a therapeutic approach towards the treatment of diseases that involve a dysregulated apoptosis pathway.
    Type: Application
    Filed: May 15, 2019
    Publication date: August 6, 2020
    Applicant: AbbVie Inc.
    Inventors: Scott L. Ackler, Erwin R. Boghaert, Milan Bruncko, George Doherty, Andrew S. Judd, Aaron R. Kunzer, Violeta L. Marin, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-fu Tao, Xilu Wang, Dennle S. Welch
  • PHARMACEUTICAL COMPOSITIONS
    Publication number: 20200246324
    Abstract: The invention provides (+)-?-dihydrotetrabenazine succinate salt. Also provided are (+)-?-dihydrotetrabenazine succinate salt for use in medicine, pharmaceutical compositions comprising (+)-?-dihydrotetrabenazine succinate salt and a pharmaceutically acceptable excipient and the uses of (+)-?-dihydrotetrabenazine succinate salt as a VMAT2 receptor antagonist and in the treatment of a movement disorder such as Tourette's syndrome. The invention further provides a method for preparing the (+)-?-dihydrotetrabenazine succinate salt.
    Type: Application
    Filed: April 17, 2020
    Publication date: August 6, 2020
    Applicant: ADEPTIO PHARMACEUTICALS LIMITED
    Inventors: Andrew John DUFFIELD, Anant PANDYA
  • METHODS OF TREATING CANCER WITH FARNESYLTRANSFERASE INHIBITORS
    Publication number: 20200246325
    Abstract: The present invention relates to the field of cancer therapy. Specifically, provided are methods of treating cancer in a subject having clinical signs of bone marrow homing of myeloid cells, including neutropenia, isolated neutropenia, a low percentage of peripheral blood blasts with or without a high percentage of bone marrow blasts, and/or a low ratio of peripheral blood blasts to bone marrow blasts, with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on hematological characteristics indicating bone marrow homing of myeloid cells.
    Type: Application
    Filed: August 7, 2018
    Publication date: August 6, 2020
    Inventor: Antonio Gualberto
  • METHODS FOR SOLID TUMOR TREATMENT
    Publication number: 20200246326
    Abstract: Disclosed herein are methods for treating solid tumors by direct injection into the tumors of chemotherapeutic particles, methods for inhibiting tumor metastasis by administering chemotherapeutic particles to a subject having a tumor, and compositions that include chemotherapeutic particles, small amounts of a polysorbate, and a carrier.
    Type: Application
    Filed: April 3, 2020
    Publication date: August 6, 2020
    Inventors: Mike Baltezor, Gere diZerega, Charles Decedue, Sam Campbell, Matt McClorey
  • QUINOLINE AMIDES AND METHODS OF USING SAME
    Publication number: 20200246327
    Abstract: The present invention provides novel compounds that are quinoline foldamers. Such foldamers stabilize and bind to islet amyloid polypeptide (IAPP). In certain embodiments, the quinoline foldamers of the invention are soluble and cross biological membranes without cellular assistance. The present invention further provides novel method of preventing or treating diabetes in a subject in need thereof by administering to the subject an effective amount of at least one quinoline foldamer of the invention. The present invention further provides novel method of preventing or treating a neurodegenerative disease caused by a misfolded and/or unstructured protein in a subject in need thereof by administering to the subject an effective amount of at least one quinoline foldamer of the invention.
    Type: Application
    Filed: October 27, 2016
    Publication date: August 6, 2020
    Inventors: Andrew MIRANKER, Sunil KUMAR
  • Method for producing benzazoloquinolium (BQs) salts and using the biological activity of the composition
    Publication number: 20200246328
    Abstract: Disclosed is the synthesis procedure for benzazolo[3,2-a]quinolinium chloride salts and the inclusion of chloro-substituent, amino-substituent, and nitro-substituent resulting in several compounds. The compounds are further used as markers due to their fluorescent properties including in hypoxic environments. This disclosure further describes anti-cancer screening of two BQS, namely, 7-benzyl-3-aminobenzimidazo[3,2-a]quinolinium chloride (ABQ-48: NSC D-763307) and the corresponding 7-benzyl-3-nitrobenzimidazo[3,2-a]quinolinium chloride (NBQ 48: NSC D-763303).
    Type: Application
    Filed: April 20, 2020
    Publication date: August 6, 2020
    Applicant: Sistema Universitario Ana G. Mendez, Inc.
    Inventors: Osvaldo Cox, Beatriz Zayas
  • NEURONAL MODULATION
    Publication number: 20200246329
    Abstract: A method for modulating an immune response by activating or inhibiting dopaminergic neurons in the Ventral Tegmental Area (VTA) is provided. Modulation is achieved by modulating the activity, the abundance or both of: a natural killer cell, a CD8 T-cell, a CD4 T-cell, a B-cell, a dendritic cell, a macrophage, a granulocyte, or their combination.
    Type: Application
    Filed: March 30, 2020
    Publication date: August 6, 2020
    Inventors: Asya ROLLS, Tamar BEN SHANNAN, Hilla AZULAY-DEBBIE, Fahed HAKIM, Maya SCHILLER, Shai SHEN-ORR, Elina STAROSVETSKY
  • ANTI-INFLAMMATORY, ANTI-CANCER, AND ANTI-ANGIOGENIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THEREOF
    Publication number: 20200246330
    Abstract: Compounds of the general Formula A-D-Y are disclosed with activity towards treating diseases related to inflammation, cancer, neurodegenerative diseases, and cardiovascular diseases. Pharmaceutical compositions, methods of making, and methods of use thereof are also described.
    Type: Application
    Filed: September 28, 2018
    Publication date: August 6, 2020
    Applicant: MEDICON PHARMACEUTICALS, INC.
    Inventor: Basil RIGAS
  • Pharmaceutical combinations and their use
    Publication number: 20200246331
    Abstract: The present disclosure relates to a pharmaceutical combination, e.g. a product, comprising a combination of (a) a MDM2 inhibitor of formula I or formula II, or a pharmaceutically acceptable salt thereof and a PKC pathway inhibitor of formula III, formula IV, formula V or formula VI or a pharmaceutically acceptable salt thereof, particularly for use in the treatment or prevention of proliferative diseases. The disclosure also relates to corresponding pharmaceutical formulations, uses, methods, combinations, data carriers and related disclosure embodiments. The disclosure further relates to use of an MDM2 inhibitor of formula I or formula II, or a pharmaceutically acceptable salt thereof, alone for use in the treatment of a proliferative disease.
    Type: Application
    Filed: August 8, 2019
    Publication date: August 6, 2020
    Inventors: Ensar Halilovic, Caroline Emery
  • CARBOSTYRIL DERIVATIVES AND MOOD STABILIZERS FOR TREATING MOOD DISORDERS
    Publication number: 20200246332
    Abstract: The pharmaceutical composition of the present invention comprises a carbostyril derivative which is a dopamine-serotonin system stabilizer and a mood stabilizer in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof. The mood stabilizer may include but is not limited to lithium, valproic acid, divalproex sodium, carbamazapine, oxcarbamazapine, zonisamide, lamotragine, topiramate, gabapentin, levetiracetam or clonazepam. These compositions are used to treat patients with mood disorders, particularly bipolar disorder with or without psychotic features, mania or mixed episodes. Methods are provided for separate administration of a carbostyril derivative and a mood stabilizer to a patient with a mood disorder.
    Type: Application
    Filed: September 20, 2019
    Publication date: August 6, 2020
    Inventors: Tetsuro Kikuchi, Taro Iwamoto, Tsuyoshi Hirose
  • METHODS FOR PRODUCING ARIPIPRAZOLE SUSPENSION AND FREEZE-DRIED FORMULATION
    Publication number: 20200246333
    Abstract: Disclosed are a method for producing an aripiprazole suspension, wherein the aripiprazole has a mean particle size of 1 to 10 ?m, the method comprising the steps of: (a) combining bulk aripiprazole and a vehicle to form a primary suspension; (b) subjecting the primary suspension to first pulverization using e.g., a high shear pulverizing machine, a dispersion machine that applies shear force to a material to be processed, a colloid mill, an ultrasonic dispersion machine, or a high-pressure jet type emulsifying dispersion machine to form a secondary suspension; and (c) subjecting the secondary suspension to second pulverization using e.g., a high-pressure jet type emulsifying dispersion machine to form a sterile final suspension; and a method for producing a freeze-dried formulation from the aripiprazole suspension.
    Type: Application
    Filed: December 6, 2019
    Publication date: August 6, 2020
    Applicant: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Shogo Hiraoka, Takakuni Matsuda, Junichi Hatanaka
  • VIGOR ENHANCEMENT VIA ADMINISTRATION OF PYRIMIDINE DERIVATIVES
    Publication number: 20200246334
    Abstract: Disclosed herein are methods for increasing the overall vigor of a subject, and/or vigor of target tissues of a subject. Exemplified herein is the utilization of pyrimidine derivatives which act to stimulate stem cell proliferation. In addition to increasing vigor, such stem cell proliferation agents (SCPA) may be used to enhance and/or improve the outcome of other therapies, and may be used in psychiatric applications. Increasing vigor in subjects is not necessarily targeted to the treatment of a disease, thus, the methods can include administration to clinically healthy animals.
    Type: Application
    Filed: April 22, 2020
    Publication date: August 6, 2020
    Inventors: Kiminobu SUGAYA, Angel ALVAREZ
  • SLEEP IMPROVING AGENT
    Publication number: 20200246335
    Abstract: The present invention provides a heat shock protein expression-inducing agent, more specifically, a heat shock protein expression-inducing agent comprising a compound represented by formula (I): wherein R is a lower alkyl, phenyl, or hydroxyphenyl, or a salt thereof.
    Type: Application
    Filed: April 3, 2020
    Publication date: August 6, 2020
    Applicants: AMINO UP CHEMICAL CO., LTD., OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Kazunori GOTO, Jun NAKAHIGASHI, Atsuya SATO, Yosuke HIRAYAMA, Moeri HORIKOSHI, Noriyuki KOUDA, Syoichiro INOUE, Ikutaro SATO, Manami KATO
  • DRY EYE TREATMENTS
    Publication number: 20200246336
    Abstract: Described herein are methods and pharmaceutical formulations for treating dry eye disease.
    Type: Application
    Filed: September 10, 2019
    Publication date: August 6, 2020
    Inventors: Douglas Michael ACKERMANN, JR., James LOUDIN, Kenneth J. MANDELL
  • ANTAGONIST OF THE FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) FOR USE IN THE TREATMENT OR THE PREVENTION OF SKELETAL DISORDERS LINKED WITH ABNORMAL ACTIVATION OF FGFR3
    Publication number: 20200246337
    Abstract: The present invention relates to the treatment or prevention of skeletal disorders, at particular skeletal diseases, developed by patients that display abnormal increased activation of the fibroblast growth factor receptor 3 (FGFR3), in particular by expression of a constitutively activated mutant of FGFR3.
    Type: Application
    Filed: October 24, 2019
    Publication date: August 6, 2020
    Inventors: Laurence LEGEAI-MALLET, Arnold MUNNICH, Patricia BUSCA, Florent BARBAULT
  • COMBINATION THERAPY
    Publication number: 20200246338
    Abstract: Reversing resistance to a B-Raf inhibitor for the treatment of a proliferative disease by obtaining a tumor sample from the patient and testing it for genetic alterations in a panel of genes comprising BRAF, CRAF, CCND1, CDK4, HER2, IGF-1R, cMET, FGFR1, FGFR2, FGFR3, EGFR, MAP2K1, MAP2K2, NRAS, KRAS, HRAS, PTEN, PIK3CA, and P16 and administering a drug combination therapy comprising the B-Raf inhibitor and a second inhibitor which overcomes resistance to the B-Raf inhibitor, which second inhibitor is selected based on genetic alterations discovered in the tumor sample.
    Type: Application
    Filed: December 20, 2019
    Publication date: August 6, 2020
    Inventors: Giordano Caponigro, Darrin Stuart, Laure De Parseval
  • NEW SALT OF N-(2,6-DIETHYLPHENYL)-8-({4-[4-(DIMETHYLAMINO) PIPERIDIN-1-YL]-2-METHOXYPHENYL}AMINO)-1-METHYL-4,5-DIHYDRO-1H-PYRAZOLO[4,3-h]QUINAZOLINE-3-CARBOXAMIDE, ITS PREPARATION, AND FORMULATIONS CONTAINING IT
    Publication number: 20200246339
    Abstract: New N-(2,6-diethylphenyl)-8-({4-[4-(dimethyl amino)piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide phosphate of formula (II): Medicaments
    Type: Application
    Filed: June 28, 2018
    Publication date: August 6, 2020
    Inventors: Massimo ZAMPIERI, Marina CALDARELLI, Ilaria CANDIANI, Matteo D'ANELLO, Germano D'ARASMO
  • USE OF COENZYME FACTOR FOR ACTIVATION OF ATP PRODUCTION IN CELL
    Publication number: 20200246340
    Abstract: Problem: to provide an activator for activating intracellular ATP production. Solution: use of a 5-deazaflavin compound represented by the following formula (I): (wherein, R1 represents a hydrogen atom, an alkyl group, a halogen-substituted alkyl group, a carboxy-substituted alkyl group, or a phenyl group, R2 represents an alkyl group, a cycloalkyl group, a phenyl-substituted lower alkyl group, a phenyl group, a phenyl group substituted by one of a halogen atom, a lower alkyl group, or a lower alkoxy group, or a lower alkyl disubstituted phenyl group, and R3 and R4 each represent a hydrogen atom, a lower alkyl group, a halogen atom, a hydroxyl group, a nitro group, a cyano group, a lower alkoxy group, a phenyl-substituted lower alkoxy, a lower alkylamino group, a phenyl-substituted lower alkylamino group, or a lower alkylsulfonyl group).
    Type: Application
    Filed: February 4, 2019
    Publication date: August 6, 2020
    Applicant: TERA STONE Co., Ltd
    Inventors: Tomohisa NAGAMATSU, Norio AKAIKE
  • PHARMACEUTICAL COMPOSITION FOR TREATING THYROID CANCER COMPRISING TYROSINE KINASE ACTIVITY INHIBITOR AS ACTIVE INGREDIENT
    Publication number: 20200246341
    Abstract: A pharmaceutical composition containing a tyrosine kinase activity inhibitor as an active ingredient may increase the expression of sodium iodide symporter in thyroid cancer cells, thereby promoting iodine uptake and killing thyroid cancer cells. Thus, the composition may be useful for the treatment of thyroid cancer.
    Type: Application
    Filed: October 19, 2018
    Publication date: August 6, 2020
    Applicant: Kyungpook National University Industry-Academic Cooperation Foundation
    Inventors: Byeong Cheol AHN, Ji Min OH
  • CONCENTRATED METHOTREXATE SOLUTIONS
    Publication number: 20200246342
    Abstract: Concentrated methotrexate solutions are described which are suitable for the use of an active substance in the production of a parenterally administered medicament for the treatment of inflammatory autoimmune diseases. The methotrexate is added to a pharmaceutically acceptable solvent at a concentration of more than 25 mg/ml.
    Type: Application
    Filed: February 25, 2020
    Publication date: August 6, 2020
    Applicant: MEDAC GESELLSCHAFT FUER KLINISCHE SPEZIALPRAEPARARATE MBH
    Inventor: Heiner WILL
  • COMPOSITION FOR TREATMENT OF MUSCULAR DISORDERS
    Publication number: 20200246343
    Abstract: The present invention relates to a pharmaceutical composition for prevention or treatment of a muscular disease, the composition comprising dimenhydrinate, harmol and/or calcium pantothenate as active ingredients. Application of dimenhydrinate, harmol, and calcium pantothenate individually has an effect of promoting myoblast proliferation and differentiation. In particular, the combination thereof has the effect of synergistically increasing the effect of promoting myoblast proliferation and differentiation. Thus, dimenhydrinate, harmol and/or calcium pantothenate may be usefully used alone or in combination for the prevention or treatment of muscular diseases, in particular sarcopenia.
    Type: Application
    Filed: April 17, 2019
    Publication date: August 6, 2020
    Applicant: ONCOCROSS CO., LTD.
    Inventors: Yi-Rang KIM, Jin-Woo CHOI
  • MITOFLAVOSCINS: TARGETING FLAVIN-CONTAINING ENZYMES ELIMINATES CANCER STEM CELLS (CSCS) BY INHIBITING MITOCHONDRIAL RESPIRATION
    Publication number: 20200246344
    Abstract: The present disclosure relates to compounds that bind to flavin-containing enzymes and inhibit mitochondrial function, referred to herein as mitoflavoscins. Methods of screening compounds for mitochondrial inhibition and anti-cancer properties are disclosed. Also described are methods of using mitoflavoscins to prevent or treat cancer, bacterial infections, and pathogenic yeast, as well as methods of using mitoflavoscins to provide anti-aging benefits. Specific mitoflavoscin compounds are also disclosed.
    Type: Application
    Filed: October 23, 2018
    Publication date: August 6, 2020
    Inventors: Michael P. LISANTI, Federica SOTGIA
  • ALDEHYDE CONJUGATES AND USES THEREOF
    Publication number: 20200246345
    Abstract: The present invention provides compounds and methods of use thereof for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Application
    Filed: October 3, 2019
    Publication date: August 6, 2020
    Inventors: Todd Brady, Scott Young, William A. Kinney
  • COMBINATION THERAPY
    Publication number: 20200246346
    Abstract: The present invention relates to a pharmaceutical combination comprising (a) a Raf inhibitor as defined herein, or a pharmaceutically acceptable salt thereof and (b) a MEK inhibitor, particularly trametinib, particularly for use in the treatment of a proliferative disease. This invention also relates to uses of such combination for preparation of a medicament for the treatment of a proliferative disease; methods of treating a proliferative disease in a subject in need thereof comprising administering to said subject a jointly therapeutically effective amount of said combination; use of such combination for the treatment of proliferative disease; pharmaceutical compositions comprising such combination and commercial packages thereto.
    Type: Application
    Filed: April 30, 2018
    Publication date: August 6, 2020
    Inventor: Vesselina COOKE
  • Substituted Pyrrolopyridine-Derivatives
    Publication number: 20200246347
    Abstract: Protein-inhibitory substituted pyrrolopyridine derivatives of formula (I) in which X, Y, R1, R2, R3 and R4 are as defined herein, to pharmaceutical compositions and combinations comprising the compounds according to the invention, and to the prophylactic and therapeutic use of the inventive compounds, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for neoplastic disorders, respectively cancer or conditions with dysregulated immune responses or other disorders associated with aberrant MAP4K1 signaling, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: June 7, 2018
    Publication date: August 6, 2020
    Applicants: BAYER PHARMA AKTIENGESELLSCHAFT, DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG
    Inventors: Norbert SCHMEES, Bernd BUCHMANN, Anders Roland FRIBERG, Hans BRIEM, Manfred HUSEMANN, Ulf BOMER, Gabriele LEDER, Rafael CARRETERO, Detlef STOCKIGT, Rienk OFFRINGA
  • METHODS, SYSTEM, AND KIT FOR MONITORING, DIAGNOSING, AND TREATING IMPULSIVE AGGRESSION
    Publication number: 20200246348
    Abstract: The present disclosure relates to the treatment of impulsive aggression with molindone as an add-on therapy where patients are already receiving treatment for the underlying disease or disorder, e.g. attention deficit hyperactivity disorder (ADHD), bipolar disorder, autism, Tourette's syndrome or post traumatic stress disorder (PTSD), using evidence-based impulsive aggression testing methodologies and systems.
    Type: Application
    Filed: April 17, 2020
    Publication date: August 6, 2020
    Applicant: Supernus Pharmaceuticals, Inc.
    Inventors: Jennifer DUGAN STOCKS, Christopher Evans, Seung Hwang, Susan M. Dallabrida
  • RET INHIBITOR
    Publication number: 20200246349
    Abstract: A compound represented by the following general formula (I) [the symbol in the formula are as defined in the description], a salt thereof, or the like is a RET inhibitor or RET tyrosine kinase inhibitor that can he used as an agent for the prevention or treatment of disorders including cancers and cancer metastasis having mutations in RET.
    Type: Application
    Filed: April 22, 2020
    Publication date: August 6, 2020
    Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventors: Tatsushi KODAMA, Hiroshi SAKAMOTO, Toshiyuki TSUKAGUCHI
  • PHENOTHIAZINE DIAMINIUM SALTS AND THEIR USE
    Publication number: 20200246350
    Abstract: Disclosed are compounds of general formula (I): and pharmaceutically acceptable salts thereof, formulations, methods and uses in, for example, the treatment of disease.
    Type: Application
    Filed: January 24, 2020
    Publication date: August 6, 2020
    Inventors: Colin Marshall, Scott Clunas, John Mervyn David Storey, James Peter Sinclair, Thomas Craven Baddeley, Ahtsham Ishaq, Michael Simpson, Craig Williamson, Barry Alan Wood, Claude Michel Wischik, Charles Robert Harrington, Janet Elizabeth Rickard, David Horsley, Yin Sze Loh, Karrar Ahmad Khan, Christopher Paul Larch
  • COMBINATIONS AND USES AND TREATMENTS THEREOF
    Publication number: 20200246351
    Abstract: Methods for treating or preventing HIV in a patient using a combination of bictegravir and lamivudine and optionally with other anti-HIV agents are disclosed, as well as compositions containing such compounds.
    Type: Application
    Filed: August 2, 2018
    Publication date: August 6, 2020
    Inventors: Mark I. COCKETT, Eugene L. STEWART, Mark Richard UNDERWOOD, Cindy L. VAVRO
  • Vanadyl and vanadate for use in reducing stress-induced metabolic derangement
    Publication number: 20200246352
    Abstract: The current invention relates to the use of a physiologically acceptable organic and/or inorganic vanadium compound or complex, such as for example bis(maltolato)oxovanadium (BMOV) in the prevention or amelioration of stress-induced metabolic derangement in a subject. More in particular, the invention relates to a physiologically acceptable organic and/or inorganic vanadium compound or complex for use in the amelioration of hyperglycemia in a subject suffering from stress such as elicited by a trauma, wherein the physiologically acceptable organic and/or inorganic vanadium compound or complex is administered to said subject before the trauma is inflicted to the subject.
    Type: Application
    Filed: September 21, 2018
    Publication date: August 6, 2020
    Applicant: CFM Pharma Holding B.V.
    Inventors: Hendrik Jan Cornelis Meijerink, Josephus Johannes de Kimpe, Lekhram Changoer
  • TRANSDERMAL AND/OR TOPICAL DELIVERY SYSTEM COMPRISING CLOBAZAM
    Publication number: 20200246353
    Abstract: A Transdermal Drug Delivery System (TDDS) of the reservoir or plaster type for administrating clobazam for the treatment of various types of anxiety and epilepsy, for 1 day, 2 day, 3 day, 4 day, 5 day, 6 day and/or 7-day continuous application.
    Type: Application
    Filed: March 31, 2020
    Publication date: August 6, 2020
    Inventors: Fotios M. Plakogiannis, Donald McAfee, Nisarg Modi
  • ADJUVANT THERAPY FOR USE IN PROSTATE CANCER TREATMENT
    Publication number: 20200246354
    Abstract: The present invention relates to the field of prostate cancer treatment, and in particular the field of prostate cancer treatment by Androgen Deprivation Therapy (ADT). The present treatment involves oral administration of an estetrol component in conjunction with ADT.
    Type: Application
    Filed: January 30, 2020
    Publication date: August 6, 2020
    Inventor: F. M. J. Debruyne
  • Glucocorticoid Particles and Their Use
    Publication number: 20200246355
    Abstract: Disclosed herein are particles of at least 95% by weight of a glucocorticoid that have a specific surface area of at least 10 m2/g, methods for making, such particles, and methods for their use as therapeutics. Also disclosed herein are particles of at least 95% by weight of an indolinone that have a specific surface area of at least 10 m2/g, methods for making such particles, and methods for-their use as therapeutics.
    Type: Application
    Filed: September 28, 2018
    Publication date: August 6, 2020
    Inventors: Michael BALTEZOR, Matthew MCCLOREY, Joseph S. FARTHING, Mark WILLIAMS, Jacob SITTENAUER
  • NEUROSTEROIDS AND ENANTIOMERS THEREOF FOR THE PREVENTION AND TREATMENT OF NEURODEGENERATIVE CONDITIONS
    Publication number: 20200246356
    Abstract: The present disclosure is directed to a composition for prevention or treatment of neurodegenerative conditions. The composition comprises a neurosteroid, a synthetic enantiomer of a neurosteroid, or a combination thereof.
    Type: Application
    Filed: February 5, 2020
    Publication date: August 6, 2020
    Applicant: Washington University
    Inventors: Douglas Covey, Charles Zorumski, Yukitoshi Izumi, Makoto Ishikawa
  • Use of Nor-Ursodeoxycholic Acid for Reducing Liver Fat
    Publication number: 20200246357
    Abstract: The present invention relates to the use of Nor-UDCA in the treatment of hepatic steatosis in patients having a hepatic fat fraction of greater than 10%.
    Type: Application
    Filed: September 28, 2018
    Publication date: August 6, 2020
    Inventors: Markus PRÖLS, Roland GREINWALD, Michael TRAUNER, Peter FICKERT
  • METHODS OF PREVENTING PLATELET ACTIVATION
    Publication number: 20200246358
    Abstract: A method of preventing or reducing the occurrence of malondiadehyde and/or levuglandin protein modification in a subject in need thereof, comprising administering to said subject an effective amount of at least one reactive dicarbonyl scavenger compound, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: April 17, 2020
    Publication date: August 6, 2020
    Inventors: John A. Oates, Olivier Boutaud, Irene Zagol-Ikapitte
  • COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC CONDITIONS
    Publication number: 20200246359
    Abstract: Methods and compositions that include the use NSAID derivatives for the treatment of disease, retinopathy, and related diseases are disclosed herein.
    Type: Application
    Filed: September 28, 2018
    Publication date: August 6, 2020
    Applicant: MEDICON PHARMACEUTICALS, INC.
    Inventor: Basil RIGAS
  • USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES
    Publication number: 20200246360
    Abstract: The present invention relates to a method for treating dermal inflammation and dermal diseases by local or systemic delivery, in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2 (FPR2).
    Type: Application
    Filed: September 10, 2019
    Publication date: August 6, 2020
    Inventors: Veena Viswanath, Richard L. Beard, John E. Donello, Edward Hsia
  • Compositions and Methods for Treatment of Fibrosis
    Publication number: 20200246361
    Abstract: The present disclosure relates, in general, to compositions comprising phosphatidylcholine and phosphatidylcholine derivatives, e.g., DLPC (1, 2-dilauroyl-sn-glycero-3-phosphocholine) or DPPC, for the treatment of fibrosis, including liver fibrosis and associated conditions such as fatty liver disease, non-alcoholic steatohepatitis (NASH) and cirrhosis, or lung fibrosis and conditions associated with lung fibrosis.
    Type: Application
    Filed: October 11, 2018
    Publication date: August 6, 2020
    Inventor: Adam Elhofy
  • Arginase Inhibitors as Therapeutics
    Publication number: 20200246362
    Abstract: Compounds according to Formula I are potent inhibitors of Arginase I and II activity: where R1, R2, R3, R4, D, W, X, Y, and Z are defined in the specification. The invention also provides pharmaceutical compositions of the compounds and methods of their use in treating or preventing a disease or a condition associated with arginase activity.
    Type: Application
    Filed: February 19, 2020
    Publication date: August 6, 2020
    Inventors: Michael Van Zandt, Gunnar E. Jagdmann
  • FORMULATIONS FOR THE DELIVERY OF AUTOPHAGY STIMULATING TREHALOSE
    Publication number: 20200246363
    Abstract: A pharmaceutically acceptable composition comprising trehalose and a pharmaceutically acceptable excipient and methods of delivering autophagy stimulating trehalose to a patient in need thereof.
    Type: Application
    Filed: August 8, 2018
    Publication date: August 6, 2020
    Inventor: Robert PETCAVICH
  • MEDICAL APPLICATION OF COMPOSITION OF FRUCTOSE-1,6-BISPHOSPHATE AND BLOOD CONCENTRATION STABILIZER THEREOF
    Publication number: 20200246364
    Abstract: Application of a composition of FBP and a blood concentration stabilizer thereof in manufacturing medicaments for preventing and treating metabolic diseases and metabolic dysfunction related diseases. The FBP may also be a pharmaceutically acceptable salt or hydrate of prototype thereof, a prodrug thereof, or a derivative thereof. The blood concentration stabilizer refers to a medicament or substance for treating diabetes capable of slowing down rapid in vivo degradation of FBP in a pharmaceutical preparation. The composition can cause a higher FBP blood concentration peak value and a more stable blood concentration, and can reduce an FBP dosage and thus can reduce the toxicity resulted from a large amount of inorganic phosphorus entering systemic circulation after degradation of a large dosage of FBP.
    Type: Application
    Filed: December 4, 2017
    Publication date: August 6, 2020
    Inventors: Xiaoyuan LIAN, Zhizhen ZHANG, Heng QIAN, Hongyun BI, Binbin CHI, Rongyao ZHU
  • COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF AS INHIBITORS OF RAN GTPASE
    Publication number: 20200246365
    Abstract: Compounds of general formula IA, IB and IC outlined below, including pharmaceutically acceptable salts, solvates and hydrates thereof. Such compounds and pharmaceutical compositions comprising them may be used in medical conditions involving Ran GTPase.
    Type: Application
    Filed: August 30, 2018
    Publication date: August 6, 2020
    Inventors: JIAN HUI WU, GERALD BATIST, XIAOCHONG TIAN, XIAOLONG LI, ANNE-MARIE MES-MASSON, DIANE PROVENCHER, EURIDICE CARMONA
  • BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES
    Publication number: 20200246366
    Abstract: Provided herein are methods of treating or ameliorating a pediatric cholestatic liver disease by non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a pediatric liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an ASBTI or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 11, 2019
    Publication date: August 6, 2020
    Applicant: Lumena Pharmaceuticals LLC
    Inventors: Bronislava GEDULIN, Michael GREY, Niall O'DONNELL
  • FLAVONOID COMPOSITIONS AND USES THEREOF
    Publication number: 20200246367
    Abstract: This invention relates to a flavonoid composition that includes eriocitrin. The flavonoid may be included in a complex with other bioflavonoids. The composition may also include neoeriocitrin. This invention also relates to methods of using the composition, including for reducing IL-6 or MCP-1 treating inflammation, and treating symptoms of metabolic syndrome.
    Type: Application
    Filed: February 6, 2020
    Publication date: August 6, 2020
    Applicants: INGREDIENTS BY NATURE, U.S. DEPARTMENT OF AGRICULTURE
    Inventors: Robert M. BREWSTER, John A. MANTHEY
  • Compositions Containing Decitabine, 5Azacytidine and Tetrahydrouridine and Uses Thereof
    Publication number: 20200246368
    Abstract: Compositions comprising decitabine and tetrahydrouridine or 5-azacytidine and tetrahydrouridine for the treatment of cancer are disclosed. The compositions in the form of a pill is administered to a human subject sequentially or alternately guided by the measurement of predictive biomarkers.
    Type: Application
    Filed: December 5, 2016
    Publication date: August 6, 2020
    Applicant: Epidestiny, Inc.
    Inventors: Yogen Saunthararajah, Joseph Desimone, Henry Lau, Santhosh Vadivelu
  • ANTISENSE OLIGONUCLEOTIDE AND COMPOSITION FOR PREVENTION OR TREATMENT OF GLYCOGEN STORAGE DISEASE TYPE IA
    Publication number: 20200246369
    Abstract: The present invention provides a novel antisense oligonucleotide and a composition for preventing or treating glycogen storage disease type Ia. The present invention provides an antisense oligonucleotide which hybridizes with a pre-mRNA sequence derived from a region including at least one of a base at position 42911000, a base at position 42911004, and a base at position 42911005 in a base sequence of human chromosome 17 of GRCh38/hg38 and has activity to inhibit aberrant splicing of pre-mRNA of c.648G>T variant G6PC.
    Type: Application
    Filed: March 9, 2018
    Publication date: August 6, 2020
    Inventors: Go TAJIMA, Satoshi OKADA, Myyuki TSUMURA
  • Methods and Compositions for RNAi Mediated Inhibition of Gene Expression in Mammals
    Publication number: 20200246370
    Abstract: Methods and compositions are provided for modulating, e.g., reducing, coding sequence expression in mammals. In the subject methods, an effective amount of an RNAi agent, e.g., an interfering ribonucleic acid (such as an siRNA or shRNA) or a transcription template thereof, e.g., a DNA encoding an shRNA, is administered to a non-embryonic mammal, e.g., via a hydrodynamic administration protocol. Also provided are RNAi agent pharmaceutical preparations for use in the subject methods. The subject methods and compositions find use in a variety of different applications, including academic and therapeutic applications.
    Type: Application
    Filed: December 20, 2019
    Publication date: August 6, 2020
    Inventors: Mark A. Kay, Anton McCaffrey
  • MALTOSYL-ISOMALTOOLIGOSACCHARIDES
    Publication number: 20200246371
    Abstract: The application describes compositions that include maltosyl-isomalto-oligosaccharides with a desirable mass average molecular weight distribution. In some cases, the compositions can contain at least 3% mannitol.
    Type: Application
    Filed: February 13, 2020
    Publication date: August 6, 2020
    Inventors: Lee Madsen II, Jack Oswald
  • METHODS OF TREATING MOTOR NEURON DISEASES
    Publication number: 20200246372
    Abstract: A method of treating a subject having MND is provided. The method comprising administering to the subject a therapeutically effective amount of an agent selected from the group consisting of miR-218, miR-218*, precursor thereof and a polynucleotide sequence encoding miR-218 or miR-218* or precursor thereof, thereby treating the MND in the subject. A method of treating a subject having MND, the method comprising administering to the subject a therapeutically effective amount of an agent capable of downregulating an activity or expression of a gene product selected from the group consisting of KCND2, KCNH1, GABRB2, SLC6A1, SLC6A11, KCNA1, CACNB4, GRIA2, GRIK2, GABRG1 and GRIK3, is also provided.
    Type: Application
    Filed: April 22, 2020
    Publication date: August 6, 2020
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Eran HORNSTEIN, Irit REICHENSTEIN, Alon CHEN